Trial · NCT03905694
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6 | Lumasiran | -71.97 | Standard Error 2.706 | percent change | |
| Percentage Change in Spot Urinary Oxalate: Creatinine Ratio in the Extension Period (Month 6 to End of Study [Month 60]) | Lumasiran | -74.48 | Standard Error 4.246 | percent change | |
| Percentage of Time That Spot Urinary Oxalate: Creatinine Ratio is at or Below the Near-normalization Threshold (≤1.5 × Upper Limit of Normal (ULN) for Age) | Lumasiran | 68.95 | Full Range 18.3 to 98.7 | percentage of time | |
| Absolute Change in Spot Urinary Oxalate: Creatinine Ratio From Baseline | Lumasiran | Month 6 | -0.4880 | Standard Error 0.09127 | mmol/mmol |
| Absolute Change in Spot Urinary Oxalate: Creatinine Ratio From Baseline | Lumasiran | Month 60 | -0.5179 | Standard Error 0.09929 | mmol/mmol |
| Percentage of Participants With Spot Urinary Oxalate: Creatinine Ratio Levels ≤ the ULN for Age | Lumasiran | 100 | percentage of participants | ||
| Percentage of Participants With Spot Urinary Oxalate: Creatinine Ratio Levels ≤ 1.5xULN for Age | Lumasiran | 100 | percentage of participants | ||
| Percentage Change in Plasma Oxalate From Baseline to End of Study (Month 60) | Lumasiran | Month 6 | -32.06 | Standard Error 6.711 | percent change |
| Percentage Change in Plasma Oxalate From Baseline to End of Study (Month 60) | Lumasiran | Month 60 | -24.78 | Standard Error 12.814 | percent change |
| Absolute Change in Plasma Oxalate From Baseline to End of Study (Month 60) | Lumasiran | Month 6 | -5.03 | Standard Error 1.294 | µmol/L |
| Absolute Change in Plasma Oxalate From Baseline to End of Study (Month 60) | Lumasiran | Month 60 | -5.03 | Standard Error 1.859 | µmol/L |
| Maximum Observed Plasma Concentration (Cmax) of Lumasiran | Lumasiran | Day 1 | 886 | Geometric Coefficient of Variation 58.9 | nanograms per milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) of Lumasiran | Lumasiran | Month 6 | 869 | Geometric Coefficient of Variation 84.0 | nanograms per milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) of Lumasiran | Lumasiran | Month 12 | 1180 | Geometric Coefficient of Variation 83.5 | nanograms per milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) of Lumasiran | Lumasiran | Month 18 | 878 | Geometric Coefficient of Variation 94.0 | nanograms per milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) of Lumasiran | Lumasiran | Month 24 | 790 | Geometric Coefficient of Variation 91.9 | nanograms per milliliter (ng/mL) |
| Time to Maximum Observed Plasma Concentration (Tmax) of Lumasiran | Lumasiran | Day 1 | 3.74 | Full Range 1.87 to 8.1 | hours (h) |
| Time to Maximum Observed Plasma Concentration (Tmax) of Lumasiran | Lumasiran | Month 6 | 4 | Full Range 1.75 to 10.1 | hours (h) |
| Time to Maximum Observed Plasma Concentration (Tmax) of Lumasiran | Lumasiran | Month 12 | 4 | Full Range 1.75 to 7.25 | hours (h) |
| Time to Maximum Observed Plasma Concentration (Tmax) of Lumasiran | Lumasiran | Month 18 | 3.64 | Full Range 1.98 to 10 | hours (h) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03905694/results